Three months on, Eli Lilly has closed the books on its search for a new chief financial officer. And as with its previous CFO ...

Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The ...

Eli Lilly ( LLY) has long been a reliable name in the healthcare sector, providing stability for investors during periods of ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and ... The drug is ...

Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U ...

In addition, Eli Lilly has still refused to lower the outrageous ... United States but just $485 in the United Kingdom and $94 in Japan. And let’s be clear: Even with this modest price reduction ...

Eli Lilly and Company has announced the FDA approval of EBGLYSS for treating atopic dermatitis in adults and children over 12 ...

Eli Lilly LLY announced positive topline results from two phase ... which already markets a once-weekly insulin called Awiqli ...

Shortly after a positive data drop for Eli Lilly’s efsitora a | Lilly revealed that its weekly insulin candidate efsitora ...

In the United States and some countries other than Europe, Lilly owns exclusive development and commercialization rights to ...